Pfizer Inc.
PFE
Clasificación en acciones
#115
Pfizer Inc. is a global biopharmaceutical leader engaged in the research,... Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Precio por acción
$30.06
Capitalización bursátil
$171.33B
Cambio (1 día)
2.02%
Cambio (1 año)
21.75%
País
US
Comercio Pfizer Inc. (PFE)
Categoría
Healthcare
Ratio P/E de Pfizer Inc. (PFE)
Ratio P/E al October 2026 TTM: 38.60
Según los últimos informes financieros y el precio de las acciones de Pfizer Inc., el P/E actual (TTM) de la empresa es 38.60. Al final de 2024, la empresa tenía un P/E de 18.74.
Historial del ratio P/E de Pfizer Inc. desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 38.60 | 111.95% |
| 2025 | 18.21 | -2.80% |
| 2024 | 18.74 | -75.40% |
| 2023 | 76.17 | 731.36% |
| 2022 | 9.16 | -38.65% |
| 2021 | 14.93 | -33.11% |
| 2020 | 22.33 | 75.65% |
| 2019 | 12.71 | -41.66% |
| 2018 | 21.79 | 126.47% |
| 2017 | 9.62 | -62.98% |
| 2016 | 25.98 | -4.22% |
| 2015 | 27.13 | 31.45% |
| 2014 | 20.64 | 21.52% |
| 2013 | 16.98 | -6.03% |
| 2012 | 18.07 | -1.86% |
| 2011 | 18.42 | 14.15% |
| 2010 | 16.13 | 15.33% |
| 2009 | 13.99 | -0.61% |
| 2008 | 14.08 | -22.47% |
| 2007 | 18.16 | 12.58% |
| 2006 | 16.13 | -24.59% |
| 2005 | 21.39 | 26.25% |
| 2004 | 16.94 | -72.58% |
| 2003 | 61.78 | 216.04% |
| 2002 | 19.55 | -35.41% |
| 2001 | 30.27 | -58.36% |
| 2000 | 72.68 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 40.53 | 5.01% |
US
|
|
| 38.50 | -0.26% |
US
|
|
| 79.88 | 106.95% |
US
|
|
| 116.96 | 203.02% |
US
|
|
| 22.25 | -42.36% |
CH
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.